Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

ClinicalTrials.gov ID: NCT00439244

Public ClinicalTrials.gov record NCT00439244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine and total hip

Study identification

NCT ID: NCT00439244
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novartis; Industry
Enrollment: 412 participants

Conditions and interventions

Conditions

Osteoporosis

Interventions

Drug

Eligibility (public fields only)

Age range: 45 Years to 89 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2006 (Type not available)
Primary completion: Feb 2009 (Actual)
Completion: Feb 2009 (Actual)
Last update posted: Apr 20, 2011

2006 – 2009

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Beverly Hills	California	90211	—
Novartis Investigative Site	La Mesa	California	—	—
Novartis Investigative Site	Oakland	California	—	—
Not listed	Colorado Springs	Colorado	80910	—
Not listed	Lakewood	Colorado	80227	—
Not listed	Gainesville	Georgia	30501	—
Not listed	Morton Grove	Illinois	60053	—
Not listed	Urbandale	Iowa	50322	—
Not listed	Bangor	Maine	04401	—
Novartis Investigative Site	Woodbury	Minnesota	—	—
Not listed	St Louis	Missouri	63110	—
Not listed	Lincoln	Nebraska	68516	—
Not listed	Albuquerque	New Mexico	87106	—
Not listed	West Haverstraw	New York	10993	—
Novartis Investigative Site	Pittsburgh	Pennsylvania	15253	—
Novartis Investigative Site	Spokane	Washington	—	—
Not listed	Madison	Wisconsin	53705	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00439244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 20, 2011 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00439244 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →